Orexo、Abera将开发基于Amorphox技术的鼻粉疫苗

2024-12-17 16:55

Orexo (OTCQX:ORXOY) has entered into a collaboration with Abera Bioscience ('Abera'), a platform and vaccine developer, to broaden the use of its powder-based drug delivery technology AmorphOX^®.
As a first step, the aim is to develop powder-based intranasal vaccine candidates, focusing on Abera's influenza vaccine candidate.
An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic, Orexo (OTCQX:ORXOY) said.
The collaboration is funded by Abera through various previously received grants, mainly from CEPI (the Coalition for Epidemic Preparedness Innovation).
Source: Press Release

More on Orexo AB